Underdiagnosis Persists Despite Clear Guidelines
A new real‑world analysis of U. S. health records shows that fewer than 1 % of adults newly diagnosed with high blood pressure are tested for primary aldosteronism. The study, conducted across multiple health systems, identified an 8.7 % positivity rate among those who were screened, meaning roughly one in twelve patients with incident hypertension had the condition.
Wellness insights
Rejection Sensitive Dysphoria: The Hidden Struggle of ADHD
Breastfeeding Trauma Leaves Women Reluctant to Have More Children
Perfectionism Linked to Higher Depression Risk
Rewiring Your Brain for Mental ResilienceResearchers examined electronic health data from over 200,000 patients who received a hypertension diagnosis between 2022 and 2025. Only 1,800 of them underwent aldosterone‑renin testing, the standard screen for primary aldosteronism. Of those tested, 156 showed elevated aldosterone levels consistent with the disorder. The investigators attribute the low screening frequency to limited awareness among clinicians and the perceived complexity of the test.
Current clinical guidelines recommend testing for primary aldosteronism in patients with resistant hypertension, hypokalemia, or early‑onset disease. Yet the study found that most physicians still rely on conventional blood pressure management without considering hormonal causes. Dr. Elena Ramirez, an endocrinologist who helped design the analysis, said, „We see a gap between guideline recommendations and everyday practice. Many doctors simply aren’t prompted to order the test.” The data also revealed regional variations, with screening rates highest in academic centers and lowest in community clinics. Patients who were screened tended to be younger and had fewer comorbidities, suggesting selection bias.
Why Are So Few Hypertensive Patients Tested for Primary Aldosteronism?
The low testing rate may stem from several factors. First, the aldosterone‑renin ratio requires fasting blood draws and careful interpretation, which can deter busy clinicians. Second, insurance coverage for the assay is inconsistent, leading to out‑of‑pocket costs for patients. Finally, the condition’s symptoms often overlap with essential hypertension, making it harder to recognize without targeted testing. „If we miss primary aldosteronism, patients remain on multiple antihypertensives that may be unnecessary,” Dr. Ramirez added. „Targeted therapy can normalize blood pressure and reduce cardiovascular risk.”
The study’s findings underscore a missed opportunity to improve hypertension control. Detecting primary aldosteronism early allows for specific treatments, such as mineralocorticoid receptor antagonists or surgery, which can dramatically lower blood pressure and curb long‑term organ damage. As awareness grows, the authors hope that electronic health record alerts and streamlined testing protocols will increase screening rates.
Frequently Asked Questions
What is primary aldosteronism? It is a hormonal disorder where the adrenal glands produce excess aldosterone, leading to sodium retention, potassium loss, and high blood pressure.
How is the condition diagnosed? Doctors typically measure the aldosterone‑renin ratio in a fasting blood sample. Abnormal results may be followed by confirmatory suppression testing or imaging.
What are the treatment options? Patients may receive mineralocorticoid receptor antagonists, such as spironolactone, or undergo surgical removal of an aldosterone‑producing adenoma if one is identified.
